Mankind Pharma News and Updates

Name: Latest research reports of Mankind Pharma Ltd. authored by FundsIndia and published by - Trendlyne research reports.
Item: Mankind Pharma Ltd.
Rating: 5
Author: FundsIndia

Keep track of all breaking news on Mankind Pharma from all sources in a single place.

Load latest

Mankind Pharma Ltd.

30 Sep 2024

2251.00

0.08%

Mankind Pharma board approves fundraising plan of up to Rs 10,000 cr

Business Standard

Mankind Pharma on Monday said it will raise up to Rs 10,000 crore via issuance of non-convertible debentures and commercial papers. The company said its board has approved to raise up to Rs 5,000 crore via non-convertible debentures in 3-4 distinct series with maturities of up to 48 months. The board's fundraising committee also approved to raise up to Rs 5,000 crore via listed and rated commercial papers, having face value as may be decided in accordance with applicable law, in one or more tranches or series, the drug maker said in a regulatory filing. The company, however, did not disclose how it aims to utilise the raised capital. In July this year, Mankind had announced the acquisition of Bharat Serums and Vaccines from Advent International for around Rs 13,630 crore. The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and consumer healthcare products. Shares of the company on Monday ended 2.68 per cent down at Rs .

Number of FII/FPI investors decreased from 648 to 627 in Sep 2025 qtr

Mankind Pharma's Approves Raising Rs 10,000 Crore Via NCDs, CPs

NDTV Profit | 30 Sep 2024 1 more

Mankind Pharma Ltd.

24 Sep 2024

2251.00

0.08%

Mankind Pharma To Raise Rs 7,000-Crore Debt For Bharat Serums Acquisition

NDTV Profit

The debt raised by Mankind Pharma will be used to bridge the time gap between the acquisition and the pre-approved QIP.

Geojit BNP Paribas upgraded Mankind Pharma Ltd. to Buy with a price target of 2600.0 on 26 Nov, 2025.

Stock to buy today: Mankind Pharma (2,651.30): BUY

Business Line | 24 Sep 2024 2 more

Mankind Pharma Ltd.

20 Sep 2024

2251.00

0.08%

Mankind Pharma to raise funds up to Rs 10k crore via debt instruments

Business Standard

The board announced the issuance of corporate guarantees for four of its subsidiaries, namely Mankind Agritech, Appian Properties, Copmed Pharmaceuticals, and Lifestar Pharma.

Geojit BNP Paribas upgraded Mankind Pharma Ltd. to Buy with a price target of 2600.0 on 26 Nov, 2025.

Broker's call: Mankind Pharma (Buy)

Business Line | 20 Sep 2024 2 more

Mankind Pharma Ltd.

17 Sep 2024

2251.00

0.08%

Mankind Pharma Calls Board Meet On Sept. 20 To Mull Fundraise

NDTV Profit

The board will explore various options for fundraise, including issue of NCDs, commercial papers or other debt securities, Mankind Pharma said.

Mankind Pharma Ltd. has an average target of 2700.00 from 2 brokers.

Mankind Pharma Ltd.

04 Sep 2024

2251.00

0.08%

Mankind Pharma shares gain after OTC biz transfer to subsidiary; details

Business Standard

Mankind Pharma share price surged after the company on Tuesday completed a business transfer agreement (BTA) to shift its over-the-counter (OTC) business to its wholly owned subsidiary

Mankind Pharma Ltd. is trading below all available SMAs

Mankind Pharma Ltd.

03 Sep 2024

2251.00

0.08%

Mankind up 3% after co looks to raise Rs 9,000 cr for Bharat Serums deal

Business Standard

Mankind Pharma is likely to raise Rs 9,000 crore through NCDs to acquire Bharat Serums and Vaccines

Mankind Pharma Ltd. has an average target of 2700.00 from 2 brokers.

Mankind Pharma plans Rs 9,000 crore raise for Bharat Serums acquisition

Business Standard | 03 Sep 2024

Mankind Pharma Ltd.

26 Aug 2024

2251.00

0.08%

Broker's call: Mankind Pharma (Buy)

Business Line

Motilal Oswal

Mankind Pharma Ltd. is trading below all available SMAs

Mankind Pharma - Improvising The Base; Adding New Avenues For Growth: Motilal Oswal

NDTV Profit | 26 Aug 2024

Mankind Pharma Ltd.

23 Aug 2024

2251.00

0.08%

FundsIndia

Mankind Pharma Ltd. is trading below all available SMAs

Mankind Pharma Ltd.

23 Aug 2024

2251.00

0.08%

Improvising the base; adding new avenues for growth

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

MANKIND has a strategic roadmap for growth through expansion in high entry barrier innovative product launches in the chronic/consumer segment and other adjacencies, transitioning from sexual wellness to consumer wellness in the over-the counter (OTC) space.

Number of FII/FPI investors decreased from 648 to 627 in Sep 2025 qtr

Mankind Pharma Ltd.

10 Aug 2024

2251.00

0.08%

What should you do with the Mankind Pharma stock post the Bharat Serums and Vaccines acquisition?

Business Line

Synergies arising from the Bharat Serums acquisition could play out over the long term, benefitting Mankind shareholders

26.31% Fall from 52W High

Mankind Pharma News and Updates

Keep track of all breaking news on Mankind Pharma from all sources in a single place.